Rubius Therapeutics is a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines. The company’s lead rare disease program is RTX-134, an investigational enzyme replacement therapy for the potential treatment of patients with phenylketonuria (PKU). Rubius is currently enrolling patients in a Phase 1 clinical study evaluating the safety and pharmacokinetics of RTX-134 in adult patients with PKU. The company also has earlier stage programs in homocystinuria and hyperoxaluria. To learn more, please visit www.rubiustx.com or www.rubiustrials.com/pku.